NovoCure Ltd. (NVCR) intrinsic value & 10-year financials
NovoCure Ltd. (NVCR) has a Graham intrinsic value of $5.98 per share. At $14.07 on Oct 17, 2026, the stock trades 135% above that value. Over the last 10 fiscal years revenue grew 25.8% a year to $655.4M, with an average return on invested capital of -161.2%.
- Graham intrinsic value
- $5.98
- Share price (Oct 17, 2026)
- $14.07
- Price vs Graham value
- 135% above
- Market cap
- $1.6B
- Revenue (FY2025)
- $655.4M
- Revenue growth (10-yr CAGR)
- 25.8%
- ROIC (10-yr avg)
- -161.2%
- Free cash flow (FY2025)
- -$75.7M
NVCR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $655.4M | -$136.2M | -$1.22 | -$75.7M | -23.5% | -38.6% |
| FY2024 | $605.2M | -$168.6M | -$1.56 | -$69.2M | -28.2% | -78.3% |
| FY2023 | $509.3M | -$207.0M | -$1.95 | -$100.4M | -45.7% | -104.1% |
| FY2022 | $537.8M | -$92.5M | -$0.88 | $9.4M | -16.6% | -33.9% |
| FY2021 | $535.0M | -$58.4M | -$0.56 | $58.6M | -8.3% | -20.0% |
| FY2020 | $494.4M | $19.8M | $0.18 | $84.2M | 6.1% | 21.5% |
| FY2019 | $351.3M | -$7.2M | -$0.07 | $16.1M | -0.3% | -12.2% |
| FY2018 | $248.1M | -$63.6M | -$0.69 | -$4.8M | -13.6% | -976.8% |
| FY2017 | $177.0M | -$61.7M | — | -$35.6M | -22.2% | -100.9% |
| FY2016 | $82.9M | -$131.8M | — | -$113.3M | -139.1% | -269.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
NovoCure Ltd is a consistent compounder, expanding top-line revenue at 25.8% annually over the past decade.
NovoCure Ltd has historically struggled to out-earn its cost of capital, averaging just -37.9% ROIC.
Over the decade, NovoCure Ltd shows that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, NovoCure Ltd is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $5.98 per share.